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principal cause of cirrhosis and hepatocellular carci-
noma and the leading indication for liver transplanta-
tion (LT) in Western countries. However, recurrent
HCV infection is common in pre-transplant HCV
RNA positive patients with an accelerated course, lead-
ing to cirrhosis in around 30% of patients ﬁve years after
LT [1]. Given the impact of HCV recurrence on graft
and patient survival, several treatment strategies have
been evaluated in order to prevent or treat HCV infec-
tion: pre-transplantation antiviral therapy, pre-emptive
therapy initiated soon after transplantation and therapy
for established post-transplant chronic hepatitis.
Although their likelihood of responding to peginterfer-
on (Peg-IFN) plus ribavirin (RBV) is less than that iden-
tiﬁed in registration trials involving non-cirrhotic
patients, those with compensated cirrhosis can achieve
response rates of up to 50%, depending on their HCV
genotype (41% for genotype 1, 73% for genotype 2–3)
[2]. In patients with decompensated cirrhosis, the treat-
ment of HCV infection has two main goals: ﬁrst, the
suppression of HCV viremia in LT candidates may
reduce or eliminate the risk of recurrent infection [3–
6], although the eﬀect of reducing the pre-transplant0168-8278/$36.00  2009 Published by Elsevier B.V. on behalf of the Europ
doi:10.1016/j.jhep.2009.01.008
Associate Editor: P.-A. Clavien
q The authors declare that they do not have anything to disclose
regarding funding from industries or conﬂict of interest with respect to
this manuscript.
* Corresponding author. Fax: +33 1 45 59 38 57.
E-mail address: didier.samuel@pbr.aphp.fr (D. Samuel).viral load in order to decrease the severity of post-trans-
plant disease progression is unknown but probably
slight [7]; and second, in the longer term, HCV clearance
in cirrhotic patients may halt disease progression and
modify the natural history of the disease [8–10]. How-
ever, this approach has displayed certain limitations in
HCV cirrhotic patients awaiting liver transplantation:
a high prevalence of genotype 1, problems in achieving
full doses of IFN and RBV because of side eﬀects, and
a risk of complications related to impaired liver func-
tion. As mentioned above, the objective is not to reduce
the viral load at transplantation because this has not
been shown to decrease the rate and severity of recur-
rence, in contrast to HBV cirrhotic patients. The aim
is either to achieve a sustained virological response
(SVR) at transplantation or an on-treatment serum
HCV RNA clearance at transplantation. In the former
case, a period of at least 24 weeks is required after the
end of treatment, which may be too long and deleterious
for patients awaiting LT. Few published studies have
investigated the role of standard IFN with or without
RBV in patients with decompensated HCV cirrhosis:
all were performed in a single center only, were not con-
trolled and varied considerably in terms of their objec-
tives (prevention of recurrence, eﬀect on the natural
history of disease), and modalities (doses, duration,
delay before LT) [3–6,8].
The study by Carrion et al. published in this issue of
the Journal, is the ﬁrst to have used Peg-IFN (alfa-2a
180 lg/week) plus RBV (dose adjusted to creatinine
clearance, 400–1200 mg/d) therapy in 51 HCV-infectedean Association for the Study of the Liver.
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apy: 15 weeks; range: 1–57 weeks) matched with 51
untreated controls [11]. However, it is a case-control
study, which is a major limitation because despite the
accurate matching of control and treated patients, a ran-
domized trial would have minimized any potential
biases. Patients who previously did not respond to com-
bination therapy, with a Child–Pugh score >12, recur-
rent encephalopathy, thrombocytopenia <30  109/L
or renal failure, were excluded. 80% of the treated
patients were infected with genotype 1, 59% suﬀered
from hepatocellular carcinoma, the median initial
MELD score was 12 (6–25), and 45%, 43% and 12%
were Child–Pugh classes A, B and C, respectively. The
use of growth factors was permitted. This study aimed
to evaluate both the prevention of HCV recurrence
post-transplant and the risk of bacterial infections dur-
ing therapy. Although the duration of follow-up is
unknown, this study was not designed to assess the eﬀect
of antiviral therapy on modifying the natural history of
cirrhosis. The virological response rate was high, since
24 treated patients (47%) achieved HCV RNA negativ-
ity during treatment, but only 15 (29%) were HCV
RNA negative at the time of transplantation (drop
outs n = 3, deaths n = 4, viral relapse n = 2) and 10
(20%) achieved an SVR after transplantation. The rate
of SVR using Peg-IFN and RBV was similar to that
reported previously with a daily, standard IFN regimen
by the same investigators [5]. One explanation could be
the large number of HCV RNA negative patients who
were not transplanted due to death (n = 4) or drop-out
(n = 3). High rates of dose reductions (49%) or discon-
tinuation of treatment (43%) because of side eﬀects
impaired the eﬃcacy of antiviral therapy. Although
the results of short-term pre-transplant treatment using
a standard IFN regimen (SVR after LT: 20%) [5] were
very similar to those achieved with standard duration
therapy (SVR after LT: 26%) [6], a longer duration of
therapy requires further investigation in order to reduce
the relapse rate. Of the patients achieving an SVR before
LT, none experienced an HCV recurrence on the graft
[6]. Post-transplant HCV recurrences in patients who
achieved an on-treatment response without an SVR
could be explained by the short duration of therapy
and the persistence of HCV in a second compartment
[5]. Liver HCV RNA levels in the explanted liver were
not determined during this study, although this might
be helpful when evaluating the risk of post-transplant
recurrence. As reported by other studies using standard
IFN, an early (or rapid) virological response and non-1
genotype were the strongest predictors of viral clearance
during therapy [5,6,8,9]. The absence of a P2 log10
reduction in HCV RNA between baseline and week 4
had a strong negative predictive value. This ﬁnding is
highly relevant, as it will enable cessation of treatment
in patients with a low probability of a response and thusreduces the risk of complications. The rate of SVR
according to genotype is not reported in this study (viral
clearance at the time of LT: 22% for genotype 1
patients), although in other studies the SVR rate with
genotype 1 was around 7–13%, as compared to 43–
67% with genotype 2–3 [5,8,9]. It should be noted that
during all these studies, the antiviral therapy regimen
was adapted to liver function (lower dosage of IFN or
RBV, shorter duration of therapy) [5,8,9]. The other
predictors of an SVR are the pre-treatment viral load
[5,9], Child–Pugh score class A (genotype 1 only) and
completion of treatment [6]. During the study in ques-
tion, individuals who achieved an SVR had a signiﬁ-
cantly lower baseline viral load compared to
virological responders who relapsed after transplanta-
tion (5.0 log10 IU/ml, 3.4–6.2 vs. 6.3 log10 IU/ml, 5.6–
6.8; p = 0.036). Liver function was not predictive of a
virological response in this cohort, although none of
the patients with a baseline Child–Pugh score of C (or
MELD > 18) achieved SVR.
The safety of Peg-IFN therapy is a major concern in
patients with decompensated cirrhosis. The reported
rates of neutropenia, thrombocytopenia, anemia, and
episodes of infection or liver decompensation during
therapy are 50–60%, 30–50%, 30–60%, 4–13% and 11–
20%, respectively [5,6,8,9]. In the present study, the inci-
dence of clinical decompensation (22% vs. 18%,
p = 0.62) and survival (death before LT 8% vs. 2%
p = 0.06; death 24 weeks after LT 8% vs. 12%;
p = 0.67) were similar in treated patients and controls.
However, the incidence of bacterial infection episodes
(mostly spontaneous bacterial peritonitis and spontane-
ous bacteremia due to Gram-negative bacilli) was higher
in treated patients (25%) than in controls (6%)
(p = 0.01). A septic shock episode occurred in 10% of
treated patients versus none in controls (p = 0.05). Vari-
ables independently associated with the occurrence of
bacterial infections were antiviral treatment and a
Child–Pugh score of B–C. In a cohort of 66 decompen-
sated HCV-infected cirrhotics treated with Peg-IFN
alfa-2b and RBV for 24 weeks vs. 63 controls, Iacobellis
et al. showed that the odds ratios in treated patients
were 2.95 for severe infection and 1.97 for death from
infection. They reported that variables independently
associated with infective episodes were Child–Pugh class
C and a neutrophil count <900 lL during treatment [8].
In the study by Crippin et al. antiviral treatment in
patients with a mean Child–Pugh score of 12 (±1.2)
was the cause of life-threatening infections, which ulti-
mately led to early discontinuation of the study [3].
Importantly, in the study by Carrion et al. the incidence
of spontaneous bacterial peritonitis in patients who were
not receiving norﬂoxacin was signiﬁcantly higher in the
treated group than in controls (log-rank = 0.012),
whereas no diﬀerence was observed in patients who were
receiving norﬂoxacin prophylaxis (log-rank = 0.62).
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apy using Peg-IFN regimens in HCV cirrhotic patients
awaiting LT is possible with a relatively high rate of
virological response (47%) and can prevent a recurrence
of HCV, especially in patients with a non-1 genotype
and an early (or rapid) virological response. The pri-
mary goals of treatment are either an SVR or an unde-
tectable HCV RNA level at the time of LT, both of
which signiﬁcantly reduce the risk of post-transplant
HCV recurrence. Because of the potential for serious
adverse events, patients should be closely monitored
during antiviral treatment and followed by centers with
considerable experience of managing decompensated
cirrhosis. This rate of severe infection during IFN ther-
apy is similar to that observed in HBV cirrhotic patients
who received pre-transplant IFN before the advent of
nucleo(s)tide analogues [12]. The best candidates for
therapy remain Child–Pugh class A patients whose viro-
logical response rate is high and in whom the risk of
side eﬀects is almost identical to that of controls. Anti-
viral therapy is currently not indicated in Child–Pugh
class C patients (or MELD > 18) because of the high
risk of septic complications during treatment and a
low SVR rate. In Child–Pugh class B patients, treat-
ment should be discussed on a case-by-case basis as a
function of baseline factors for a potential response
(i.e., genotype non-1, viral load) with virological moni-
toring at weeks 4 and 12. In this way, antiviral therapy
can be discontinued after 4 or 12 weeks if there is no
virological response. Antibiotic prophylaxis and the
use of growth factors may facilitate antiviral therapy
in patients with poor liver function. The risk/beneﬁt
ratio of treating Child–Pugh class B patients in order
to prevent HCV recurrence still needs to be determined
by randomized controlled trials. The new classes of
potent and direct antiviral agents are not yet available
for patients with decompensated HCV cirrhosis. How-
ever, it is probably this group of patients who will ben-
eﬁt the most, and the time has come for a shift towards
novel therapeutic strategies.References
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